CHEST 2022, News
The CLEAR study compared clinical outcomes and health resource usage in patients with severe asthma who continued, switched, or stopped their biologic treatment.
News
In a study, the calcineurin inhibitor tacrolimus proved to be noninferior to intravenous cyclophosphamide.
News
The updated labeling is based on results from a safety management cohort from the ZUMA-1 study.
News
The approval was based on data from the phase 3 JADE clinical trial program, which included the JADE MONO-1, JADE MONO-2, and JADE COMPARE trials.
News
The approval was based on data from three phase 3 trials that evaluated the efficacy and safety of upadacitinib in patients 12 years of age and older with moderate to severe atopic dermatitis who are candidates for systemic therapy.
News
Zolgensma is an adeno-associated virus vector-based gene therapy.
News
The approval was based on data from the randomized, double-blind, placebo-controlled phase 3 VOYAGE trial.
CHEST 2021, News
Research presented at CHEST 2021 assessed an alternative approach to predicting COPD exacerbations during the COVID-19 pandemic.
CHEST 2021, News
A post-hoc analysis of the VENTURE trial evaluated whether baseline oral corticosteroid dosage affected the efficacy of dupilumab in improving severe asthma outcomes.
CHEST 2021, News
NAVIGATOR trial results presented at CHEST 2021 show the effect of tezepelumab on peak expiratory flow rates in severe asthma.
